SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Advanced Environmental Petroleum (AEPP)

AEPP RSS Feed
Add AEPP Price Alert      Hide Sticky   Hide Intro
Moderator: BottomWatcher , Rat Fink, fuzzymcilwoods, BillyParks, ninersax, BLight1911
Search This Board: 
Last Post: 8/22/2017 11:16:53 PM - Followers: 163 - Board type: Free - Posts Today: 0

 

BIOTECH Merger in Action


April 24 Interview with CEO Michael Redman
 
 


On April 6, 2017, in connection with the change of control of the Company, Mr. Kistler resigned as the Company’s sole director, executive officer and other positions and Mr. Redman was appointed a director and our chief executive officer and president and J. Donald Payne as a director and our Secretary and chief accounting officer of the Company.



Verified Company Profile  4/10/2017
Email: mredman@oncolixbio.com
 

AEPP (Advanced Environmental Petroleum Producers) Oncolix, Inc. has become the controlling shareholder

https://www.sec.gov/Archives/edgar/data/1574061/000147793217001787/aepp_sc13d.htm
https://www.sec.gov/Archives/edgar/data/1584137/000147793217001656/aepp_8k.htm



AEPP enters into a SPA (Share Purchase Agreement) with Oncolix, Inc. 


Initial agreement was made on March 7, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74041605

http://ih.advfn.com/p.php?pid=nmona&article=74093500

Merger expected to be finalized on or around April 3, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74157198

AEPP UPDATE:

Change of control of AEPP has been filed with the Florida Secretary of State showing Oncolix CEO

Michael Redman and Oncolix director, Donald Payne as controlling officers of AEPP.

 
AEPP Security Details
Share Structure
  Market Value1 $3,571,704 a/o Apr 07, 2017
Authorized Shares 500,000,000 a/o Mar 30, 2017
Outstanding Shares 93,911,633 a/o Apr 04, 2017
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 33,311,633 a/o Apr 06, 2017
  Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders
Shareholders of Record 101 a/o Apr 06, 2017

 


Zero outstanding debt

"approximately $111,928 of the $315,000 purchase price will be utilized by the Seller to pay all outstanding indebtedness and financial obligations of the Company so that immediately following the closing of the Share Acquisition (the “ SPAClosing ” ), the Company will have no outstanding indebtedness and/or other financial obligations."
http://ih.advfn.com/p.php?pid=nmona&article=74093500 

April 3, 2017 SPA closing date expected
Due to unanticipated circumstances, the mailing did not occur. As a result, we filed Amendment No. 1 to the Original Filing on March 21, 2017, ( “ Amendment No.1 and together with the Original Filing, collectively, the “ Information Statement ” ), anticipate March 22, 2017 to be the new mailing date and the date of the Board Change and the SPA Closing to occur on or about April 3, 2017 (but in no event earlier than 10 days after the actual mailing date).

Filings from Oncolix after closing will be expected within 4 business days which will detail merger.
Consequently, many more news events will follow with Oncolix releasing details of their business and status of Prolanta as it goes through FDA clinical trials.


 

Who is Oncolix, Inc.?

https://oncolixbio.com

April 2017 Company Presentation:
https://nebula.wsimg.com/8b544fcbb6f5bf5fb52c1c7e5a69eb81?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

POST ACQUISITION INTERVIEW WITH CEO MICHAEL REDMAN

https://www.youtube.com/watch?v=Ox6n1HH8v_0&feature=youtu.be
 

Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas. We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer.  This clinical trial is expected to begin in late 2015. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.   

The FDA has also approved the designation of 
Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity. 

Prolanta is currently in FDA clinical trials phase 1. 
https://clinicaltrials.gov/ct2/show/NCT02534922

Oncolix received Orphan Drug Status for their developmental drug Prolanta.
http://www.bizjournals.com/houston/news/2013/04/24/oncolix-poised-to-start-phase-i-trials.html

8 U.S. Patents have been awarded in the development of Prolanta
http://oncolixbio.com/patents.html

 

PATENTS

The eight US Patents issued to Oncolix are listed in the following table. Non-US patents or applications are not listed.

Patent Number Issue Date Issued To Title
US 7,115,556 03 OCT 2006 Oncolix Use of Anti-Prolactin Agents to Treat Proliferative Conditions
US 7,201,905 10 APR 2007 Oncolix Bi-Functional Cancer Treatment Agents
US 7,339,027

US 8,304,381
4 MAR 2008

6 NOV 2012
Oncolix Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
US 7,632,809 15 DEC 2009 Oncolix Multimeric Ligands with Enhanced Stability
US 8,648,046

US 8,754,035
11 FEB 2014

17 JUN 2014
Oncolix Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells
US 8,754,031 17 JUN 2014 Oncolix Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/neu Signaling Pathway

Notable excerpt from company website
Our initial focus is ovarian cancer, and we have an FDA-cleared Investigational New Drug (IND) application to commence a Phase I human trial. Based on our preclinical evidence of expected efficacy, the FDA has also granted Prolanta™ Orphan Drug status for the treatment of ovarian cancer.  Our collaborators at The University Texas MD Anderson Cancer Center developed the efficacy data in ovarian cancer, which was published in Cell Reports (see Scientific Publications). These researchers demonstrated that Prolanta™ has a novel mechanism of action, induced autophagy) against ovarian cancer, and also demonstrated the synergy of Prolanta™ with other chemotherapy drugs. See Ovarian Cancer and Prolanta™.

 

 

The Oncolix Team

Management

\

\

Board Members

\

\

\

Company Advisors

\

\

\



 





 


https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12149068

AEPP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AEPP News: Proxy Statement - Other Information (preliminary) (pre 14c) 08/22/2017 06:06:03 AM
AEPP News: Quarterly Report (10-q) 08/18/2017 05:09:11 PM
AEPP News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 08/14/2017 12:12:18 PM
AEPP News: Initial Statement of Beneficial Ownership (3) 08/11/2017 02:25:22 PM
AEPP News: Initial Statement of Beneficial Ownership (3) 08/11/2017 01:17:26 PM
News News Alert: Proxy Statement - Other Information (preliminary) (pre 14c) 08/22/2017 06:06:03 AM
PostSubject
#10523  Sticky Note LOL, laraz... reaper247 08/22/17 12:51:59 AM
#10441  Sticky Note PAGE 18 OF AEPP 10Q MENTIONS "$8 MILLION_FINANCING_LISTING_TO_NASDAQ_OR_NYSE"!!! Rat Fink 08/20/17 03:42:13 PM
#8084  Sticky Note AEPP/Oncolix summary. reaper247 07/20/17 06:32:22 PM
#10586   AEPP SHAREHOLDERS HOLDING ONTO THEIR SHARES!!!_ONLY_49,382_VOLUME_TODAY!!! Rat Fink 08/22/17 11:16:53 PM
#10585   Neither, she is hanging around for fun Eltp 08/22/17 11:09:14 PM
#10584   Since you have been posting here for a Sungod95 08/22/17 10:59:16 PM
#10583   I'm not going to get out of AEPP BLight1911 08/22/17 10:32:15 PM
#10582   Because any mention of Lifetech Capital will send laraz5 08/22/17 10:27:25 PM
#10581   Nope, to my knowledge, no one has mentioned Bored Lawyer 08/22/17 09:58:43 PM
#10580   Did anyone notice this new line on the website... steadyhand 08/22/17 09:48:22 PM
#10579   $ AEPP No one has mention LifeTech capital ncj167 08/22/17 07:31:26 PM
#10578   Yes all in due tim for this to skyrocket. Sungod95 08/22/17 07:12:39 PM
#10576   PoC Capital is mentioned in the Oncolix two BLight1911 08/22/17 05:42:24 PM
#10574   I sure hope so, I'm riding all free BLight1911 08/22/17 04:57:59 PM
#10573   Ticker change not happening for at least another DayDreeming 08/22/17 04:56:56 PM
#10572   All in due time DayDreeming 08/22/17 04:43:54 PM
#10571   This shouldn't be shocking to anyone. Nothing BlackDoggie 08/22/17 04:37:18 PM
#10570   I can't even find any dirt on Daron dabullishbear 08/22/17 03:48:33 PM
#10569   I can't find any connection between him and BLight1911 08/22/17 03:47:26 PM
#10566   What is the connection between Oncolix and Daron dabullishbear 08/22/17 03:36:38 PM
#10565   Categorically false. All that information is absolutely wrong. zen222 08/22/17 03:32:26 PM
#10563   Speaking of Rats let's see who turns on laraz5 08/22/17 03:27:51 PM
#10561   It is a Shame that Redman or Payne laraz5 08/22/17 03:12:54 PM
#10560   That's a fact!!!!!! arbytrader 08/22/17 02:58:40 PM
#10559   Oncolix worth at least as much as Innovation dabullishbear 08/22/17 02:52:52 PM
#10557  Restored Absolutely the PPS already has the fake merger laraz5 08/22/17 02:11:16 PM
#10556   Great news with the filing this morning. Bored Lawyer 08/22/17 01:55:10 PM
#10554   There hasn't been a ticker change. Wrong board... BLight1911 08/22/17 01:37:14 PM
#10552   100% false!! Current name reflects shell company, CatfishHunter 08/22/17 01:27:31 PM
#10551   I've been here since the Nigel Bosworth days. steadyhand 08/22/17 01:18:31 PM
#10550   Incorrect. Hey what happened? Weren't we supposed to steadyhand 08/22/17 01:15:14 PM
#10549   PPS already reflects ticker change. DayDreeming 08/22/17 01:12:00 PM
#10548   Guess we'll have good idea when we get CatfishHunter 08/22/17 01:07:30 PM
#10547   Oncolix name change hitting the newswires. Should start dabullishbear 08/22/17 12:59:02 PM
#10546   The updates are picking up in frequency.... watchers steadyhand 08/22/17 12:30:55 PM
#10545   Updated news on the website... https://www.oncolixbio.com/news-and-events.html AltJactUp 08/22/17 12:30:19 PM
#10544   Redman sure has been fast paced ...just thinking Pinky4 08/22/17 12:29:40 PM
#10543   WEBPAGE UPDATES LETS GO! steadyhand 08/22/17 12:29:39 PM
#10542   Hey let's get this ibox cleaned up. Time steadyhand 08/22/17 12:26:11 PM
#10541   Oncolix has all the necessary SEC filings completed. CatfishHunter 08/22/17 12:20:59 PM
#10540   Let's go Billydakidd 08/22/17 12:02:25 PM
#10539   Name change process has begun, lets get this microcaptrdr24 08/22/17 11:25:54 AM
#10538   This morning's filing was huge. Perhaps the most steadyhand 08/22/17 10:11:47 AM
#10537   Agree, September onward will be epic Eltp 08/22/17 09:45:35 AM
#10536   Nice! I'm pretty sure Oncolix now has 10 CatfishHunter 08/22/17 09:14:54 AM
#10535   Name change https://www.sec.gov/Archives/edgar/data/1584137/000147793217004134/0 BLight1911 08/22/17 08:59:25 AM
#10534   PRE 14-C is out : molee 08/22/17 08:28:33 AM
#10533   Another outstanding post Reaper, I never seen a Eltp 08/22/17 08:02:24 AM
#10532   A few days...maybe a week or two. reaper247 08/22/17 01:56:10 AM
#10531   the call to buy came from dis ncj167 08/22/17 01:38:42 AM
#10530   That's awesome then, my mistake. Wish I had BLight1911 08/22/17 01:34:38 AM
#10529   U missed the zero in that post :) ncj167 08/22/17 01:32:11 AM
#10528   I'm sure it will take a while for BLight1911 08/22/17 01:29:45 AM
PostSubject